Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery
Preijers, T.; Hazendonk, H. C.A.M.; Liesner, R.; Chowdary, P.; Driessens, M. H.E.; Hart, D.; Keeling, D.; Laros-van Gorkom, B. A.P.; van der Meer, F. J.M.; Meijer, K.; Fijnvandraat, K.; Leebeek, F. W.G.; Collins, P. W.; Cnossen, M. H.; Mathôt, R. A.A.; the OPTI-CLOT study group
(2018) Journal of Thrombosis and Haemostasis, volume 16, issue 11, pp.
(Article)
Abstract
Essentials Factor IX (FIX) dosing using body weight frequently results in under and overdosing during surgery. We aimed to establish a population pharmacokinetic (PK) model describing the perioperative FIX levels. Population PK parameter values for clearance and V1 were 284 mL h−170 kg−1 and 5450 mL70 kg−1. Perioperative PK parameters
... read more
differ from those during non-surgical prophylactic treatment. Summary: Background Hemophilia B is a bleeding disorder characterized by a deficiency of coagulation factor IX (FIX). In the perioperative setting, patients receive FIX concentrates to ensure hemostasis. Although FIX is usually dosed according to bodyweight, under- and overdosing occurs frequently during surgery. Aim The objective was to quantify and explain the interpatient variability of perioperatively administered plasma-derived (pd) and recombinant (r) FIX concentrates. Methods Data were collected from 118 patients (median age, 40 years [range, 0.2–90]; weight, 79 kg [range, 5.3–132]) with moderate (28%) or severe hemophilia B (72%), undergoing 255 surgical procedures. Population pharmacokinetic (PK) parameters were estimated using nonlinear mixed-effect modeling in NONMEM. Results Measured perioperative FIX level vs. time profiles were adequately described using a three-compartment PK model. For a typical 34-year-old patient receiving rFIX, clearance (CL), intercompartmental clearance (Q2, Q3), distribution volume of the central compartment (V1) and peripheral compartments (V2, V3) plus interpatient variability (%CV) were: CL, 284 mL h−170 kg−1 (18%); V1, 5450 mL70 kg−1 (19%); Q2, 110 mL h−170 kg−1; V2, 4800 mL70 kg−1; Q3, 1610 mL h−170 kg−1; V3, 2040 mL70 kg−1. From 0.2 years, CL and V1 decreased 0.89% and 1.15% per year, respectively, until the age of 34 years. Patients receiving pdFIX exhibited a lower CL (11%) and V1 (17%) than patients receiving rFIX. Interpatient variability was successfully quantified and explained. Conclusions The estimated perioperative PK parameters of both pdFIX and rFIX are different from those reported for prophylactic treatment. The developed model may be used to apply PK-guided dosing of FIX concentrates during surgery.
show less
Download/Full Text
Keywords: coagulation factor concentrates, coagulation factor IX, hemophilia B, pharmacokinetics, surgery, Hematology
ISSN: 1538-7933
Publisher: Wiley-Blackwell
Note: Funding Information: B. A. P. Laros-van Gorkom has received unrestricted educational grants from Baxter and CSL Behring. F. J. M. van der Meer received grants from Bayer, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Sanquin and Sobi for the development of a registry of Hemophilia patients in the Netherlands (HemoNED). K. Meijer has received research support from Bayer, Sanquin and Pfizer; speaker fees from Bayer, Sanquin, Boehringer Ingelheim, BMS and Aspen; and consulting fees from uniQure. The institution of K. Fijnvandraat has received unrestricted research grants from CSL Behring, Bayer and Novo Nordisk and her institution received consultancy fees from Shire, Roche, Novo Nordisk and Bayer. F. W. G. Leebeek has received unrestricted research grants from CSL Behring and Shire, outside the submitted work, and is consultant for Shire, uniQure and Novo Nordisk (DSMB), for which the fees go to the institution. P. W. Collins has received funding for research from CSL Behring, and paid consultancy from Shire, Novo Nordisk, CSL and Roche. M. H. Cnossen has received unrestricted research grants for investigator-initiated studies and educational as well as travel grants from Pfizer, Baxalta/Shire, Bayer, CSL Behring, Novo Nordisk, Novartis, Nordic Pharma, and for advisory board activities from Bayer and Roche. R. Mathôt has received travel grants from Shire and Bayer. The remaining authors declare no competing financial interests. Publisher Copyright: © 2018 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis
(Peer reviewed)